The non-melanoma skin cancer market will register a CAGR of almost 6% by 2022

Thursday, January 10, 2019 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Jan. 9, 2019 /PRNewswire/ -- About this marketSurgery is considered as the first line curative approach

for NMSC, despite the presence of an extensive range of non-surgical treatment modalities. This is because surgery results in the highest cure rate. Surgical treatment provides superior outcomes regarding complete lesion response, clearance of NMSC,
cumulative recurrence probabilities compared with cryotherapy, photodynamic therapy, radiotherapy, 5-FU, and imiquimod. Technavio's analysts have predicted that the non-melanoma skin cancer market will register a CAGR of almost 6% by 2022.Read the full report: https://www.reportlinker.com/p05691253 Market OverviewIncrease in incidence of NMSCThe white population in Europe, the US, and Australia are highly affected by NMSC, and the incidence of NMSC is increasing. Globally, NMSC differs significantly. Lower incidence rates are are registered in African countries and higher rates are observed in Australia. THE NMSC incidence rate is low in other parts of Europe compare to UK.Few drugs in pipeline for NMSCThe drug pipeline for NMSC has very few molecules because of the low amount of R&D in this area. Non-disease modifying drugs are under evaluation. Most drugs are being evaluated for palliative care or as an adjuvant therapy. Various studies are being conducted to test newer targeted drugs for the treatment of advanced SCC.For the detailed list of factors that will drive and challenge the growth of the non-melanoma skin cancer market during the 2018-2022, view our report.Competitive LandscapeThe market appears to be concentrated and with the presence of several companies including Bausch Health and F. Hoffmann-La Roche, the competitive environment is quite intense. Factors such as the increasing incidence of NMSC and NMSC coverage and support, will provide considerable growth opportunities to non-melanoma skin cancer manufactures. Bausch Health, F. Hoffmann-La Roche, Sun Pharmaceuticals, and 3M Pharmaceuticals are some of the major companies covered in this report.Read the full report: https://www.reportlinker.com/p05691253 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-non-melanoma-skin-cancer-market-will-register-a-cagr-of-almost-6-by-2022-300775736.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store